Mediar Therapeutics
Mediar Therapeutics is a clinical stage company advancing first-in-class therapies to halt fibrosis progression.
Founded 2019
Boston, United States
55 employees
Series A
Total: $85.00M
Biotechnology, Health Care +1
Boston, United States
55 employees
Series A
Total: $85.00M
Biotechnology, Health Care +1
General Information
Company Name
Mediar Therapeutics
Founded Year
2019
Location
Boston, United States
Boston, United States
Employees
55
Industries
Biotechnology, Health Care, Health and Wellness
Funding Stage
Series A
BounceWatch is an independent company data service, not affiliated with Mediar Therapeutics. To contact Mediar Therapeutics, visit mediartx.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Mediar Therapeutics compare?
A PDF of Mediar Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Mediar Therapeutics soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Biotechnology
About Mediar Therapeutics
Business keywords: biotech company, fibrosis treatment, preclinical stage, novel targets, blood biomarkers, disease progression, clinical development
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series A | $85.00M | 10 |
|
15 Mar 2023 |
| Seed Round | Undisclosed | - |
|
17 Mar 2021 |
| Seed Round | Undisclosed | - |
|
01 Jan 2019 |
Mediar Therapeutics Alternatives & Competitors
View All Alternatives
Mediar Therapeutics vs
MDI Therapeutics, Inc.
United States
Developing novel serpin-based therapies
Series A
5 employees
Biotechnology, Health and Wellness
Mediar Therapeutics vs
NovaBiotics Ltd
United Kingdom
Developing first-in-class solutions for unmet health and personal care needs
Grant
14 employees
Biotechnology, Health Care
Mediar Therapeutics vs
Pre-clinical stage biotech company developing an antibody immunotherapy drug for cancer using an “In...
Angel
1 employees
Biotechnology, Health Care
FAQ About Mediar Therapeutics
Mediar Therapeutics is a clinical stage company advancing first-in-class therapies to halt fibrosis progression.
Mediar Therapeutics was founded in 2019.
Mediar Therapeutics is headquartered in Boston, United States.
Mediar Therapeutics operates in Biotechnology, Health Care and Health and Wellness. Its work centres on biotech company, fibrosis treatment, preclinical stage and novel targets.
Mediar Therapeutics has approximately 55 employees.
Mediar Therapeutics has completed 3 funding rounds, raising a total of $85.00M. The latest funding stage is Series A.
Top alternatives and competitors to Mediar Therapeutics include MDI Therapeutics, Inc., NovaBiotics Ltd, Novelogics Biotechnology Inc., Visterra Inc., NeuroSense Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Mediar Therapeutics and MDI Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Mediar Therapeutics, https://bouncewatch.com/company/mediar-therapeutics, updated 30 June 2026. When citing, please name BounceWatch and link this page.
